Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Miroslaw A. Mazurczak

Hematology Oncology | Hematology | Oncology
Sanford Medical Center
4405 E 26th St, 
Sioux Falls, SD 
Accepting New Patients
Offers Telehealth
Distinguished in WT1-Related Wilms Tumor Syndromes
Sanford Medical Center
4405 E 26th St, 
Sioux Falls, SD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Miroslaw Mazurczak is a Hematologist Oncology specialist and a Hematologist in Sioux Falls, South Dakota. Dr. Mazurczak is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Bone Marrow Aspiration. Dr. Mazurczak is currently accepting new patients.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in SD
Hospital Affiliations
Prairie Lakes Healthcare System, Inc
Sanford Vermillion Hospital
Sanford Worthington Medical Center
Sanford Canby Medical Center
Sanford Usd Medical Center
Languages Spoken
English
Polish
Russian
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 11 Less Insurance Carriers -

Locations

SANFORD MEDICAL CENTER
4405 E 26th St, Sioux Falls, SD 57103
Other Locations
SANFORD MEDICAL CENTER
1309 W 17 St, Sioux Falls, SD 57104
SANFORD HEALTH NETWORK
1018 6th Ave, Worthington, MN 56187

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Carboplatin, Paclitaxel
Study Phase: Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 2
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug, Radiation, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Cetuximab
Study Phase: Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

11 Total Publications

Final Report on NCCTG N0877 (Alliance): A Phase II Randomized, Placebo-Controlled Trial of Chemoradiotherapy with or without Dasatinib for Glioblastoma.
Final Report on NCCTG N0877 (Alliance): A Phase II Randomized, Placebo-Controlled Trial of Chemoradiotherapy with or without Dasatinib for Glioblastoma.
Journal: Neuro-oncology
Published: January 23, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mark R. Huber
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Mark R. Huber
Hematology Oncology | Hematology | Oncology

Avera Mckennan

1325 S Cliff Ave, 
Sioux Falls, SD 
 (2.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Huber is a Hematologist Oncology specialist and a Hematologist in Sioux Falls, South Dakota. Dr. Huber is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Large-Cell Immunoblastic Lymphoma, Familial Wilms Tumor 2, Chromophobe Renal Cell Carcinoma, and Bone Marrow Aspiration. Dr. Huber is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Christopher J. Sumey
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Christopher J. Sumey
Hematology Oncology | Hematology | Oncology

Sanford Medical Center

1309 W 17 St, Suite 101, 
Sioux Falls, SD 
 (3.6 miles away)
605-328-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Sumey is a Hematologist Oncology specialist and a Hematologist in Sioux Falls, South Dakota. Dr. Sumey is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Sumey is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Heidi A. Mckean
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Heidi A. Mckean
Hematology Oncology | Hematology | Oncology

Avera Mckennan

1325 S Cliff Ave, 
Sioux Falls, SD 
 (2.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Heidi Mckean is a Hematologist Oncology specialist and a Hematologist in Sioux Falls, South Dakota. Dr. Mckean is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Familial Pancreatic Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Familial Colorectal Cancer. Dr. Mckean is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mazurczak's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 62 Advanced Conditions
    View All 148 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile